Vectura Group PLC (VEC) Given Average Recommendation of “Buy” by Brokerages

Vectura Group PLC (LON:VEC) has been given an average rating of “Buy” by the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is GBX 174.86 ($2.37).

A number of research analysts have commented on the company. Shore Capital restated a “buy” rating on shares of Vectura Group in a research note on Thursday, November 9th. Numis Securities restated a “buy” rating and issued a GBX 205 ($2.78) target price on shares of Vectura Group in a research note on Thursday, October 5th. Peel Hunt reiterated a “hold” rating and set a GBX 160 ($2.17) price target on shares of Vectura Group in a research note on Thursday, January 4th. Royal Bank of Canada upgraded Vectura Group to a “sector performer” rating and set a GBX 119 ($1.61) price target for the company in a research note on Thursday, December 14th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Vectura Group in a research note on Monday.

Shares of Vectura Group (VEC) remained flat at $GBX 111.80 ($1.52) during midday trading on Friday. Vectura Group has a one year low of GBX 86.50 ($1.17) and a one year high of GBX 166.97 ($2.26).

ILLEGAL ACTIVITY WARNING: “Vectura Group PLC (VEC) Given Average Recommendation of “Buy” by Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/vectura-group-plc-vec-given-average-recommendation-of-buy-by-brokerages.html.

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply